目次

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Viral Vectors and Plasmid DNA Manufacturing Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Rising Demand for Viral Vectors Manufacturing for the R&D and Production of Gene Therapy Solutions
3.3.1.2 Advancements in Biotechnology, Facilitating Precision Medicine And Innovative Therapies
3.3.1.3 Increasing Investments in Viral Vector Technologies by Biopharmaceutical Companies and CROs
3.3.1.4 Rising Outsourcing of Viral Vector Manufacturing
3.3.2 Market Restraining Factors
3.3.2.1 High Costs Associated with Viral Vector and Plasmid DNA Manufacturing
3.3.2.2 Stringent Government Regulation is Hindering the Market Growth
3.3.2.3 High Cost Associated with Gene & Cell Therapy
3.3.2.4 Challenges Associated with Scaling Up Production While Maintaining Quality and Consistency
3.3.2.5 Intense Competition Among Vendors
3.3.3 Market Opportunities
3.3.3.1 Investments in New Production Facilities and Partnerships To Meet The Growing Demand For Viral Vectors
3.3.3.2 Expanding Applications in the Fields of Regenerative Medicine, Gene Therapy, and Vaccine Development
3.3.3.3 Innovations in Manufacturing Processes
3.4 U.S. Tariffs: What’s the Impact on Global Viral Vectors and Plasmid DNA Manufacturing Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.2.5 Timeframe for Recovery
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Market Dynamics and Demand Recovery
3.4.3.4 Policy and Funding Support
3.4.3.5 Timeframe for Recovery
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
3.4.6 Impact of U.S. and China Trade War on Viral Vectors and Plasmid DNA Manufacturing Market
3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Regulatory Framework
3.6 Emerging Markets and Megatrends
3.7 Porter’s Five Forces Analysis
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Competitive Rivalry
3.7.4 Threat of Substitutes
3.7.5 Threat of New Entrants
3.8 PEST Analysis

4 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
4.4 Viral Vectors
4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.4.3 Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
4.4.4 Adeno-Associated Viruses (AAVs)
4.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.4.2 Market Share by Region, 2025 & 2035 (%)
4.4.5 Lentiviruses
4.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.5.2 Market Share by Region, 2025 & 2035 (%)
4.4.6 Adenoviruses
4.4.6.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.6.2 Market Share by Region, 2025 & 2035 (%)
4.4.7 Retroviruses
4.4.7.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.7.2 Market Share by Region, 2025 & 2035 (%)
4.4.8 Others
4.4.8.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.8.2 Market Share by Region, 2025 & 2035 (%)
4.5 Plasmid DNA
4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
4.5.2 Market Share by Region, 2025 & 2035 (%)

5 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Product and Service
5.1 Key Findings
5.2 Product and Service Segment: Market Attractiveness Index
5.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
5.4 Product
5.4.1 Market Size by Region, 2025-2035 (US$ Billion)
5.4.2 Market Share by Region, 2025 & 2035 (%)
5.5 Services
5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Workflow
6.1 Key Findings
6.2 Workflow Segment: Market Attractiveness Index
6.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
6.4 Downstream Manufacturing
6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.4.3 Downstream Manufacturing Market Size Estimation and Forecast by Type
6.4.4 Purification
6.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.4.2 Market Share by Region, 2025 & 2035 (%)
6.4.5 Fill Finish
6.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.5.2 Market Share by Region, 2025 & 2035 (%)
6.5 Upstream Manufacturing
6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.2 Market Share by Region, 2025 & 2035 (%)
6.5.3 Upstream Manufacturing Market Size Estimation and Forecast by Type
6.5.4 Vector Amplification and Expansion
6.5.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.4.2 Market Share by Region, 2025 & 2035 (%)
6.5.5 Vector Recovery/Harvesting
6.5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.5.2 Market Share by Region, 2025 & 2035 (%)

7 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Application
7.1 Key Findings
7.2 Application Segment: Market Attractiveness Index
7.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
7.4 Vaccine Development
7.4.1 Market Size by Region, 2025-2035 (US$ Billion)
7.4.2 Market Share by Region, 2025 & 2035 (%)
7.5 Cell Therapy
7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 Gene Therapy
7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
7.6.2 Market Share by Region, 2025 & 2035 (%)
7.7 Antisense & RNAi Therapy
7.7.1 Market Size by Region, 2025-2035 (US$ Billion)
7.7.2 Market Share by Region, 2025 & 2035 (%)
7.8 Others
7.8.1 Market Size by Region, 2025-2035 (US$ Billion)
7.8.2 Market Share by Region, 2025 & 2035 (%)

8 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Indication
8.1 Key Findings
8.2 Indication Segment: Market Attractiveness Index
8.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
8.4 Cancer
8.4.1 Market Size by Region, 2025-2035 (US$ Billion)
8.4.2 Market Share by Region, 2025 & 2035 (%)
8.5 Infectious Diseases
8.5.1 Market Size by Region, 2025-2035 (US$ Billion)
8.5.2 Market Share by Region, 2025 & 2035 (%)
8.6 Genetic Disorders
8.6.1 Market Size by Region, 2025-2035 (US$ Billion)
8.6.2 Market Share by Region, 2025 & 2035 (%)
8.7 Others
8.7.1 Market Size by Region, 2025-2035 (US$ Billion)
8.7.2 Market Share by Region, 2025 & 2035 (%)

9 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by End-user
9.1 Key Findings
9.2 End-user Segment: Market Attractiveness Index
9.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-user
9.4 Biotechnology and Biopharmaceutical Companies
9.4.1 Market Size by Region, 2025-2035 (US$ Billion)
9.4.2 Market Share by Region, 2025 & 2035 (%)
9.5 CDMOs
9.5.1 Market Size by Region, 2025-2035 (US$ Billion)
9.5.2 Market Share by Region, 2025 & 2035 (%)
9.6 Academics and Research Institutes
9.6.1 Market Size by Region, 2025-2035 (US$ Billion)
9.6.2 Market Share by Region, 2025 & 2035 (%)
9.7 Others
9.7.1 Market Size by Region, 2025-2035 (US$ Billion)
9.7.2 Market Share by Region, 2025 & 2035 (%)

10 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis
11.1 Key Findings
11.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
11.3 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
11.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
11.5 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
11.5.1 North America Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
11.6 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
11.7 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
11.7.1 North America Downstream Manufacturing Market Size Estimation and Forecast by Type
11.7.2 North America Upstream Manufacturing Market Size Estimation and Forecast by Type
11.8 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
11.9 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
11.10 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
11.11 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Analysis
11.12 Canada Viral Vectors and Plasmid DNA Manufacturing Market Analysis

12 Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.1 Key Findings
12.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
12.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
12.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
12.5 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
12.5.1 Europe Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
12.6 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
12.7 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
12.7.1 Europe Downstream Manufacturing Market Size Estimation and Forecast by Type
12.7.2 Europe Upstream Manufacturing Market Size Estimation and Forecast by Type
12.8 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
12.9 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
12.10 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
12.11 Germany Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.12 UK Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.13 France Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.14 Italy Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.15 Spain Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.16 Russia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.17 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.18 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Analysis
12.19 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

13 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.1 Key Findings
13.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
13.3 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
13.4 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
13.5 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
13.5.1 Asia Pacific Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
13.6 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
13.7 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
13.7.1 Asia Pacific Downstream Manufacturing Market Size Estimation and Forecast by Type
13.7.2 Asia Pacific Upstream Manufacturing Market Size Estimation and Forecast by Type
13.8 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
13.9 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
13.10 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
13.11 Japan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.12 China Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.13 India Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.14 Australia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.15 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Analysis
13.16 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

14 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.1 Key Findings
14.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
14.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
14.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
14.5 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
14.5.1 Latin America Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
14.6 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
14.7 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
14.7.1 Latin America Downstream Manufacturing Market Size Estimation and Forecast by Type
14.7.2 Latin America Upstream Manufacturing Market Size Estimation and Forecast by Type
14.8 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
14.9 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
14.10 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
14.11 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.12 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.13 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.14 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
14.15 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

15 MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.1 Key Findings
15.2 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
15.3 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
15.4 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
15.5 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
15.5.1 MEA Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
15.6 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
15.7 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
15.7.1 MEA Downstream Manufacturing Market Size Estimation and Forecast by Type
15.7.2 MEA Upstream Manufacturing Market Size Estimation and Forecast by Type
15.8 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
15.9 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
15.10 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
15.11 GCC Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.12 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.13 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

16 Company Profiles
16.1 Competitive Landscape, 2024
16.2 Strategic Outlook
16.3 Lonza Group Ltd.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2020-2024
16.3.3.2 R&D, 2020-2024
16.3.3.3 Regional Market Shares, 2024
16.3.4 Product Benchmarking
16.3.5 Strategic Outlook
16.3.6 SWOT Analysis
16.4 Merck KGaA
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2020-2024
16.4.3.2 R&D, 2020-2024
16.4.3.3 Regional Market Shares, 2024
16.4.4 Product Benchmarking
16.4.5 Strategic Outlook
16.4.6 SWOT Analysis
16.5 uniQure N.V.
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2020-2024
16.5.3.2 R&D, 2020-2024
16.5.3.3 Business Market Shares, 2024
16.5.4 Product Benchmarking
16.5.5 Strategic Outlook
16.6 Catalent Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2020-2024
16.6.3.2 R&D, 2020-2024
16.6.3.3 Business Market Shares, 2024
16.6.4 Product Benchmarking
16.6.5 Strategic Outlook
16.6.6 SWOT Analysis
16.7 Thermo Fisher Scientific Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2020-2024
16.7.3.2 R&D, 2020-2024
16.7.3.3 Regional Market Shares, 2024
16.7.3.4 Business Market Shares, 2024
16.7.4 Product Benchmarking
16.7.5 Strategic Outlook
16.7.6 SWOT Analysis
16.8 Charles River Laboratories
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2020-2024
16.8.3.2 Regional Market Shares, 2024
16.8.4 Product Benchmarking
16.8.5 Strategic Outlook
16.8.6 SWOT Analysis
16.9 FUJIFILM Diosynth Biotechnologies
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Product Benchmarking
16.9.4 Strategic Outlook
16.10 bluebird bio Inc.
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2020-2024
16.10.3.2 R&D, 2020-2024
16.10.4 Product Benchmarking
16.10.5 Strategic Outlook
16.11 Aldevron
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Product Benchmarking
16.11.4 Strategic Outlook
16.12 Addgene
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Product Benchmarking
16.12.4 Strategic Outlook
16.13 Creative Biogene
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Product Benchmarking
16.14 VIVEbiotech
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2020-2024
16.14.4 Product Benchmarking
16.14.5 Strategic Outlook
16.15 Recipharm AB
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2020-2024
16.15.4 Product Benchmarking
16.15.5 Strategic Outlook
16.16 Waisman Biomanufacturing
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Product Benchmarking
16.17 VGXI, Inc.
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Product Benchmarking
16.17.4 Strategic Outlook
16.18 Batavia Biosciences B.V.
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Product Benchmarking
16.18.4 Strategic Outlook
16.19 WuXi AppTec
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.1 Financial Analysis
16.19.1.1 Net Revenue, 2020-2024
16.19.1.2 Regional Market Shares, 2024
16.19.1.3 Business Segment Market Shares, 2024
16.19.2 Product Benchmarking
16.19.3 Strategic Outlook
16.20 ATUM
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Product Benchmarking
16.20.4 Strategic Outlook
16.21 Altogen Biosystems
16.21.1 Company Snapshot
16.21.2 Company Overview
16.21.3 Product Benchmarking
16.21.4 Strategic Outlook
16.22 GENEZEN
16.22.1 Company Snapshot
16.22.2 Company Overview
16.22.3 Product Benchmarking
16.22.4 Strategic Outlook
16.23 SK pharmteco
16.23.1 Company Snapshot
16.23.2 Company Overview
16.23.3 Financial Analysis
16.23.3.1 Net Revenue, 2020-2024
16.23.4 Product Benchmarking
16.23.5 Strategic Outlook
16.24 Cytiva
16.24.1 Company Snapshot
16.24.2 Company Overview
16.24.3 Product Benchmarking
16.24.4 Strategic Outlook
16.25 Virovek
16.25.1 Company Snapshot
16.25.2 Company Overview
16.25.3 Product Benchmarking
16.25.4 Strategic Outlook
16.26 Advanced BioScience Laboratories Inc. (ABL)
16.26.1 Company Snapshot
16.26.2 Company Overview
16.26.3 Product Benchmarking
16.26.4 Strategic Outlook
16.27 3PBIOVIAN
16.27.1 Company Snapshot
16.27.2 Company Overview
16.27.3 Product Benchmarking
16.27.4 Strategic Outlook
16.28 BioNTech SE
16.28.1 Company Snapshot
16.28.2 Company Overview
16.28.3 Financial Analysis
16.28.3.1 Net Revenue, 2020-2024
16.28.3.2 R&D, 2020-2024
16.28.4 Product Benchmarking
16.28.5 Strategic Outlook
16.29 RegenxBio Inc.
16.29.1 Company Snapshot
16.29.2 Company Overview
16.29.3 Financial Analysis
16.29.3.1 Net Revenue, 2020-2024
16.29.3.2 R&D, 2020-2024
16.29.4 Product Benchmarking
16.30 Novartis
16.30.1 Company Snapshot
16.30.2 Company Overview
16.30.3 Financial Analysis
16.30.3.1 Net Revenue, 2020-2024
16.30.3.2 R&D, 2020-2024
16.30.3.3 Regional Market Shares, 2024
16.30.3.4 Business Segment Market Shares, 2024
16.30.4 Product Benchmarking
16.30.5 Strategic Outlook
16.31 Boehringer Ingelheim International GmbH
16.31.1 Company Snapshot
16.31.2 Company Overview
16.31.3 Financial Analysis
16.31.3.1 Net Revenue, 2020-2024
16.31.3.2 R&D, 2020-2024
16.31.3.3 Regional Market Shares, 2024
16.31.3.4 Business Segment Market Shares, 2024
16.31.4 Product Benchmarking
16.31.5 Strategic Outlook
16.32 Amicus Therapeutics
16.32.1 Company Snapshot
16.32.2 Company Overview
16.32.3 Financial Analysis
16.32.3.1 Net Revenue, 2020-2024
16.32.3.2 R&D, 2020-2024
16.32.4 Product Benchmarking
16.32.5 Strategic Outlook

17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

List of Tables
Table 1 Viral Vectors and Plasmid DNA Manufacturing Market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
Table 2 Approved Cellular and Gene Therapy Products, 2025
Table 3 Viral Vectors and Plasmid DNA Manufacturing Market: International Trade Tariff Impact Recovery Scenarios Snapshot
Table 4 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
Table 5 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 6 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 7 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 8 Viral Vectors Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 9 Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 10 Adeno-Associated Viruses (AAVs) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 11 Lentiviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 12 Adenoviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 13 Retroviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 14 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 15 Plasmid DNA Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 16 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 17 Product Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 18 Services Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 19 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 20 Downstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 21 Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 22 Purification Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 23 Fill Finish Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 24 Upstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 25 Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 26 Vector Amplification and Expansion Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 27 Vector Recovery/Harvesting Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 28 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 29 Vaccine Development Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 30 Cell Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 31 Gene Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 32 Antisense & RNAi Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 33 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 34 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 35 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 36 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 37 Genetic Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 38 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 39 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 40 Biotechnology and Biopharmaceutical Companies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 41 CDMOs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 42 Academics and Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 43 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 44 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 45 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 46 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 47 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 48 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 49 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 50 North America Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 51 North America Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 52 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 53 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 54 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 55 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 56 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 57 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 58 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 59 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 60 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 61 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 62 Europe Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 63 Europe Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 64 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 65 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 66 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 67 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 68 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 69 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 71 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 72 Russia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 73 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 74 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 76 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 77 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 78 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 79 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 80 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 81 Asia Pacific Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 82 Asia Pacific Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 83 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 84 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 85 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 86 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 87 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 88 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 89 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 90 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 91 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 92 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 93 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 94 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 95 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 96 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 97 Latin America Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 98 Latin America Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 99 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 100 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 101 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 102 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 103 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 104 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 105 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 106 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 107 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 108 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 109 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 110 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 111 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 112 MEA Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 113 MEA Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 114 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 115 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 116 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 117 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 118 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 119 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 120 Strategic Outlook
Table 121 Lonza Group Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Lonza Group Ltd.: Product Benchmarking
Table 123 Lonza: Strategic Outlook
Table 124 Lonza: SWOT Analysis
Table 125 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Merck KGaA: Product Benchmarking
Table 127 Merck KGaA: Strategic Outlook
Table 128 Merck KGaA: SWOT Analysis
Table 129 uniQure N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 uniQure N.V. : Product Benchmarking
Table 131 uniQure N.V.: Strategic Outlook
Table 132 Catalent Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Catalent Inc.: Product Benchmarking
Table 134 Catalent Inc.: Strategic Outlook
Table 135 Catalent Inc.: SWOT Analysis
Table 136 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Thermo Fisher Scientific Inc.: Product Benchmarking
Table 138 Thermo Fisher Scientific Inc.: Strategic Outlook
Table 139 Thermo Fisher Scientific Inc.: SWOT Analysis
Table 140 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Charles River Laboratories: Product Benchmarking
Table 142 Charles River Laboratories: Strategic Outlook
Table 143 Charles River Laboratories: SWOT Analysis
Table 144 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 FUJIFILM Diosynth Biotechnologies: Product Benchmarking
Table 146 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
Table 147 bluebird bio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 148 bluebird bio Inc.: Product Benchmarking
Table 149 bluebird bio Inc.: Strategic Outlook
Table 150 Aldevron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 151 Aldevron: Product Benchmarking
Table 152 Aldevron: Strategic Outlook
Table 153 Addgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 154 Addgene: Product Benchmarking
Table 155 Addgene: Strategic Outlook
Table 156 Creative Biogene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 157 Creative Biogene: Product Benchmarking
Table 158 VIVEbiotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 159 VIVEbiotech: Product Benchmarking
Table 160 VIVEbiotech: Strategic Outlook
Table 161 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 162 Recifarm AB: Product Benchmarking
Table 163 Recipharm AB: Strategic Outlook
Table 164 Waisman Biomanufacturing: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 165 Waisman Biomanufacturing: Product Benchmarking
Table 166 VGXI, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 167 VGXI, Inc. : Product Benchmarking
Table 168 VGXI Inc.: Strategic Outlook
Table 169 Batavia Biosciences B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 170 Batavia Biosciences B.V. : Product Benchmarking
Table 171 Batavia Biosciences B.V.: Strategic Outlook
Table 172 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 173 Wuxi AppTec: Product Benchmarking
Table 174 WuXi AppTec: Strategic Outlook
Table 175 ATUM: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 176 ATUM: Product Benchmarking
Table 177 ATUM: Strategic Outlook
Table 178 Altogen Biosystems: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 179 Altogen Biosystems: Product Benchmarking
Table 180 Altogen Biosystems: Strategic Outlook
Table 181 Genezen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 182 Genezen: Product Benchmarking
Table 183 GENEZEN: Strategic Outlook
Table 184 SK pharmteco: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 185 SK pharmteco: Product Benchmarking
Table 186 SK pharmteco: Strategic Outlook
Table 187 Cytiva: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 188 Cytiva: Product Benchmarking
Table 189 Cytiva: Strategic Outlook
Table 190 Virovek: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 191 Virovek : Product Benchmarking
Table 192 Virovek: Strategic Outlook
Table 193 Advanced BioScience Laboratories Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 194 Advanced BioScience Laboratories Inc.: Product Benchmarking
Table 195 Advanced BioScience Laboratories Inc.: Strategic Outlook
Table 196 3PBIOVIAN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 197 3PBIOVIAN: Product Benchmarking
Table 198 3PBIOVIAN: Strategic Outlook
Table 199 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 200 BioNTech SE: Product Benchmarking
Table 201 BioNTech SE: Strategic Outlook
Table 202 RegenxBio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 203 RegenxBio Inc.: Product Benchmarking
Table 204 Novartis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 205 Novartis: Product Benchmarking
Table 206 Novartis: Strategic Outlook
Table 207 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 208 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 209 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 210 Amicus Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 211 Amicus Therapeutics : Product Benchmarking
Table 212 Amicus Therapeutics: Strategic Outlook

List of Figures
Figure 1 Viral Vectors and Plasmid DNA Manufacturing Market Segmentation
Figure 2 Viral Vectors and Plasmid DNA Manufacturing Market by Type: Market Attractiveness Index
Figure 3 Viral Vectors and Plasmid DNA Manufacturing Market by Product and Service: Market Attractiveness Index
Figure 4 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
Figure 5 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
Figure 6 Viral Vectors and Plasmid DNA Manufacturing Market by Indication: Market Attractiveness Index
Figure 7 Viral Vectors and Plasmid DNA Manufacturing Market by End-user: Market Attractiveness Index
Figure 8 Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index by Region
Figure 9 Viral Vectors and Plasmid DNA Manufacturing Market: Market Dynamics
Figure 10 Viral Vectors and Plasmid DNA Manufacturing Market: Impact Analysis
Figure 11 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 12 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 13 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 14 Short Term & Long Term Planning
Figure 15 Impact of U.S. and China Trade War
Figure 16 Most Impacted Countries
Figure 17 Viral Vectors and Plasmid DNA Manufacturing Market: Porter’s Five Forces Analysis
Figure 18 Viral Vectors and Plasmid DNA Manufacturing Market: PEST Analysis
Figure 19 Viral Vectors and Plasmid DNA Manufacturing Market by Type: Market Attractiveness Index
Figure 20 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 21 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 22 Viral Vectors Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 23 Viral Vectors Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 24 Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 25 Viral Vectors Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 26 Adeno-Associated Viruses (AAVs) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 27 Adeno-Associated Viruses (AAVs) Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 28 Lentiviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 29 Lentiviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 30 Adenoviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 31 Adenoviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 32 Retroviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 33 Retroviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 34 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 35 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 36 Plasmid DNA Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 37 Plasmid DNA Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 38 Viral Vectors and Plasmid DNA Manufacturing Market by Product and Service: Market Attractiveness Index
Figure 39 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 40 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025, 2030, 2035 (%)
Figure 41 Product Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 42 Product Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 43 Services Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 44 Services Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 45 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
Figure 46 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 47 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025, 2030, 2035 (%)
Figure 48 Downstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 49 Downstream Manufacturing Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 50 Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 51 Downstream Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 52 Purification Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 53 Purification Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 54 Fill Finish Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 55 Fill Finish Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 56 Upstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 57 Upstream Manufacturing Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 58 Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 59 Upstream Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 60 Vector Amplification and Expansion Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 61 Vector Amplification and Expansion Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 62 Vector Recovery/Harvesting Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 63 Vector Recovery/Harvesting Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 64 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
Figure 65 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 66 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025, 2030, 2035 (%)
Figure 67 Vaccine Development Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 68 Vaccine Development Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 69 Cell Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 70 Cell Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 71 Gene Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 72 Gene Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 73 Antisense & RNAi Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 74 Antisense & RNAi Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 75 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 76 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 77 Viral Vectors and Plasmid DNA Manufacturing Market by Indication: Market Attractiveness Index
Figure 78 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 79 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025, 2030, 2035 (%)
Figure 80 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 81 Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 82 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 83 Infectious Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 84 Genetic Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 85 Genetic Disorders Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 86 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 87 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 88 Viral Vectors and Plasmid DNA Manufacturing Market by End-user: Market Attractiveness Index
Figure 89 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR %)
Figure 90 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-user, 2025, 2030, 2035 (%)
Figure 91 Biotechnology and Biopharmaceutical Companies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 92 Biotechnology and Biopharmaceutical Companies Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 93 CDMOs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 94 CDMOs Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 95 Academics and Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 96 Academics and Research Institutes Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 97 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 98 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 99 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025 and 2035 (Revenue, CAGR%)
Figure 100 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Region 2025, 2030, 2035 (%)
Figure 101 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Billion, AGR %)
Figure 102 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 103 North America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 104 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 105 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 106 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 107 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 108 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 109 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 110 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 111 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 112 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 113 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 114 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 115 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 116 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 117 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 118 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 119 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 120 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 121 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 122 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
Figure 123 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
Figure 124 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 125 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 126 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 127 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 128 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 129 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 130 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 131 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
Figure 132 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 133 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 134 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
Figure 135 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
Figure 136 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
Figure 137 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
Figure 138 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 139 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 140 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 141 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
Figure 142 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
Figure 143 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
Figure 144 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
Figure 145 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
Figure 146 Eur